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Abstract Activity of carnosinase (CN1), the only dipep-
tidase with substrate specificity for carnosine or homocar-
nosine, varies greatly between individuals but increases
clearly and significantly with age. Surprisingly, the lower
CN1 activity in children is not reflected by differences in
CN1 protein concentrations. CN1 is present in different
allosteric conformations in children and adults since all sera
obtained from children but not from adults were positive in
ELISA and addition of DTT to the latter sera increased
OD450 values. There was no quantitative difference in the
amount of monomeric CN1 between children and adults.
Further, CN1 activity was dose dependently inhibited by
homocarnosine. Addition of 80 lM homocarnosine lowered
Vmax for carnosine from 440 to 356 pmol/min/lg and
increased Km from 175 to 210 lM. The estimated Ki for
homocarnosine was higher (240 lM). Homocarnosine
inhibits carnosine degradation and high homocarnosine
concentrations in cerebrospinal fluid (CSF) may explain the
lower carnosine degradation in CSF compared to serum.
Because CN1 is implicated in the susceptibility for diabetic
nephropathy (DN), our findings may have clinical impli-
cations for the treatment of diabetic patients with a high risk
to develop DN. Homocarnosine treatment can be expected
to reduce CN1 activity toward carnosine, resulting in higher
carnosine levels.
Keywords Carnosine  Homocarnosine  Carnosinase 
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Introduction
Carnosine is a ß-alanyl-L-histidine dipeptide found in high
concentrations in the muscle but also in the central nervous
system (for review see Crush 1970) from where it is
released into the serum and cerebrospinal fluid. The role of
carnosine is not completely understood (Bauer 2005; Quinn
et al. 1992; Boldyrev and Severin 1990); it appears to
function as an antioxidant and free radical scavenger (Ba-
ran 2000; Trombley et al. 2000; Boldyrev 1993, Boldyrev
et al. 1993), can delay senescence of cultured fibroblasts
(McFarland and Holliday 1994), may serve as an anti-
glycation agent (Hipkiss 1998) and has a positive effect on
red blood cell deformability (Aydogan et al. 2008). In the
central nervous system, carnosine meets many criteria for a
neurotransmitter (Baslow 2009) modulating synaptic pro-
cesses but also appears to be involved in neuroprotection
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(Tabakman et al. 2002). Treatment with carnosine signifi-
cantly reduced infarct volume and improved neurological
function in a mouse model of ischaemic stroke (Min et al.
2008). Treatment with ß-alanine increased muscle carno-
sine concentrations (Kendrick et al. 2008; Baguet et al.
2009). Whereas there seems to be no positive effect of
muscle carnosine loading on muscle strength (Kendrick
et al. 2008), we can conclude from the data reported by
Baguet et al. that carnosine is a stable compound in human
skeletal muscle. A comparison of carnosine content
between a group of elderly Korean males and young elite
Korean swimmers showed no difference in muscle carno-
sine concentration (Kim 2009). Recently, we reported
evidence that carnosine acts as a protective factor for the
development of nephropathy in diabetes (Janssen et al.
2005). Carnosine is found in a low concentration (usually
below 100 nM) in blood and cerebrospinal fluid (CSF).
Homocarnosine (c-aminobutyric acid-L-histidine) also has
a low concentration in blood (around 100 nM) but the
concentration is much higher (up to 4 lM) in brain and
CSF where it may act as a precursor for the neurotrans-
mitter GABA (Perry et al. 1974). Homocarnosine con-
centration in the brain is about 100-fold higher than
carnosine concentration (Gjessing et al. 1990) and its
concentration in children’s CSF is higher than in adults
(Perry et al. 1968).
Two dipeptidases are known to cleave carnosine,
denoted CN1 and CN2 (Teufel et al. 2003) and classified as
members of the M20 metalloprotease family. CN2 func-
tions as a cytosolic non-specific dipeptidase (EC 3.4.13.18)
and is not present in serum or CSF. CN2 does not degrade
homocarnosine and hydrolyzes carnosine only at alkaline
pH (Teufel et al. 2003). CN1 represents human serum
carnosinase (EC 3.4.13.20), the only dipeptidase with
substrate specificity for carnosine or homocarnosine. The
CN1 gene is expressed in the central nervous system of
adults and to a lesser extent in liver (Teufel et al. 2003).
The concentrations of CN1, carnosine and homocarnosine
have been reported to vary greatly between individuals.
Both enzyme and dipeptides are found only in small
amounts in newborns (Lenney et al. 1982). CN1 activity
increases with age; it is higher in females than males
(Bando et al. 1984).
Reduced carnosinase activity (Willi et al. 1997) has
been reported in patients with certain muscle disorders
(Bando et al. 1990, Duane and Peters 1988) as well as in
patients with Parkinson disease, multiple sclerosis or
cerebrovascular accidents. In contrast, normal serum car-
nosinase activity was reported in patients with idiopathic
epilepsy and motor neuron disease (Wassif et al. 1994).
Recently, Balion et al. (2007) showed that patients with
dementia had significant lower carnosinase activities in
serum compared to controls. It remains unclear whether the
reduced activities in some patients are disease-related or
have an independent cause, for example reduced liver
function.
Although serum carnosinase activity has been well
characterized (Lenney et al. 1985; Pegova et al. 2000;
Dunnett et al. 2002; Teufel et al. 2003) using carnosine as a
substrate, homocarnosine metabolism and the differential
effects of the two primary substrates on CN1 activity have
not been studied in detail. Furthermore, little is known
concerning the relationship between carnosine and homo-
carnosine concentrations and CN1 activity in CSF. Here we
report that homocarnosine has a strong, competitive
inhibitory effect on carnosine turnover mediated by CN1.
Our results extend the understanding of brain carnosine and
homocarnosine metabolism, as well as carnosine regulation
in other tissues, and may have implications for the treat-
ment of diabetic nephropathy.
Materials and methods
Study cohort
Blood samples were obtained from healthy controls for
measuring CN1 activity and protein concentration as
described above. Healthy controls consisted of 108 adults
(range 19–62 years, 36 male and 72 female) and 52 infants
and young children (range 6 days–18 years). There was no
significant age different between male and female indi-
viduals. All participants or their parents gave informed
consent. Further, cerebrospinal fluid was obtained from
anonymised spare material in 27 children in whom a
lumbar puncture was performed in as a diagnostic measure
but in whom other CSF tests showed normal results. The
study was approved by the ethical committee (Second
Ethics Committee of the Heidelberg University; amend-
ment no. 2 and 3 to ethical approval no. 0193/2001).
Dipeptide concentrations and CN1 activity
Carnosine and homocarnosine concentrations were mea-
sured fluorometically by high-performance liquid chroma-
tography as previously described by Jansen et al. (2006)
and Scho¨nherr (2002). CN1 activity was assayed according
to a method described by Teufel et al. (2003). Briefly, the
reaction was initiated by addition of carnosine and/or
homocarnosine to serum or recombinant enzyme. The
reaction was stopped after defined periods by adding 1%
trichloracetic acid. Liberated histidine was derivatized by
adding o-pthaldialdehyde (OPA) and fluorescence was read
using a MicroTek plate reader (kExc 360 nm, kEm 460 nm).
Recombinant human CN1 was obtained from R&D Sys-
tems (Minneapolis, USA).
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CN1 ELISA
To assess the amount of CN1 protein we developed a
capture ELISA for the detection of human CN1. To this
end, we raised monoclonal antibodies against recombinant
human CN1. Balb/c mice were immunized with the
recombinant protein and boosted after 2 and 4 weeks,
respectively. Serum was collected to assess the antibody
titre. Hereafter, the mice were sacrificed and splenocytes
were fused with SP2/0 myeloma cells according to stan-
dard procedures. After fusion, the cells were plated at a
density of 0.5 cells/well. Wells containing proliferating
cells were tested for the presence of anti-carnosinase
antibody by indirect immune fluorescence (IIF). Positive
cultures were subsequently seeded at a density of 0.5 cells/
well and restested by IIF. Two stable anti-carnosinase
clones, i.e. RKYS1 and RYSK173 (both IgG1), were
selected for further analysis. The antibodies recognize an
epitope in, or near, the dimerization domain of the CN1
protein.
A human CN1 ELISA was developed by coating high
absorbant microtitre plates (Greiner BioChemia, Flacht,
Germany) overnight with 100 ll of goat polyclonal anti-
human CN1 (10 lg/ml) (R&D, Wiesbaden Germany). The
plates were extensively washed and incubated with 5% W/
V of dry milk powder to avoid nonspecific binding. For
each sample and standard serial dilutions were carried out.
The plates were placed on a shaker for 1 h and subse-
quently extensively washed with PBS/Tween. Hereafter
purified anti-human carnosinase monoclonal IgG (clone
RKYS1 or RYSK173, both gave identical results) was
added for 1 h followed by extensively washing. Biotinyl-
ated goat anti-mouse IgG was added for 1 h followed by
avidin-HRP. The plates were washed after each incubation.
After addition of deep-blue peroxidase (POD) substrate
(Roche diagnostics, Mannheim, Germany) the reaction was
stopped after 15 min by addition of 50 ll of 1 M H2SO4
and read in an ELISA reader at 450 nm. CN1 protein
concentrations were assessed in the linear part of the
dilution curve. Sensitivity of the ELISA was approximately
20 ng/ml.
Western blot analysis
Fifteen microliter of human serum was depleted for albu-
min and immunoglobulin using a commercially available
kit (Ammersham, Freiburg, Germany). After depletion, the
sample was approximately 409 diluted. Ten microliter of
the diluted sample was denatured by boiling for 10 min in
b-mercaptoethanol containing Laemmli sample buffer
(Bio-Rad, Mu¨nchen, Germany) prior to separation by 10%
SDS–PAGE. In some experiments N-deglycosylation was
performed by PNGase F treatment. Thereafter proteins
were precipitated from the diluted sample by addition of 5
volumes of acetone and subsequently centrifuged for
10 min at 15.000 RPM. The pellet was dissolved in
denaturation buffer (5% SDS, 20 mM Tris pH 7.5, 0.4 M
DTT) and process as recommended by the manufacturer
(New England Biolabs, Frankfurt, Germany). After elec-
trophoresis proteins were transferred to a PVDF membrane
(Roche, Mannheim, Germany) using semi-dry blotting.
Membranes were blocked for 1 h at room temperature with
5% non-fat dry milk powder dissolved in Tris-buffered
saline (TBS) containing 0.1% Tween 20 (Sigma, Stein-
heim, Germany). The blots were incubated overnight at
4C with a mouse monoclonal anti-CN1 antibody (Atlas
Antibodies, Stockholm, Sweden). After washing with TBS/
Tween, the membranes were incubated with a horseradish
peroxidase—conjugated secondary antibody (Santa Cruz
Biotechnology, Heidelberg, Germany) for 1 h at room
temperature. Immunoreactive bands were visualized using
chemiluminescence (PerkinElmer, Boston, USA).
Results
Carnosine and homocarnosine degradation in serum
and CSF
CN1 activity for carnosine as a substrate shows great
variability but clearly increases with age for both serum
(Fig. 1) and CSF (data not shown). CN1 activity was
considerably higher in serum than in CSF (Table 1), and
serum activities were non-significantly higher in females
(3.4 ± 1.1 lmol/ml/h, n = 62) than in males (2.9 ±
0.8 lmol/ml/h, n = 32).
Homocarnosinase activity was below the detection limit
in young children in both CSF and sera. For older controls,
activities ranged from 0.12 to 0.14 lmol/ml/h in serum and
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Fig. 1 CN1 activity in serum comparing both substrates (carnosine
and homocarnosine) in healthy controls. CN1 activity varies between
individuals and increases with carnosine as substrate (triangle) as a
function of age, whereas CN1 activity with homocarnosine as
substrate (square) is generally lower and remains stable with
increasing age
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from 0.07 to 0.11 lmol/ml/h in CSF. The increase of CN1
activity with age was much less pronounced for homo-
carnosine than for carnosine (Fig. 1), and activity for
homocarnosine was not significantly different in serum and
CSF (Table 1). Furthermore the gender difference was less
pronounced for homocarnosine than for carnosine
(females = 0.113 ± 0.05, males = 0.109 ± 0.06). Carno-
sine turnover increased with increasing carnosine concen-
trations, while increasing homocarnosine concentrations
did not lead to a significant increase in homocarnosine
turnover, suggesting that enzyme saturation is already
achieved at homocarnosine concentrations of 40 lmol/l.
Because CN1 activity for carnosine as substrate
increased in an age-dependent fashion, we next assessed if
the amount of CN1 protein was different in children and
adults. In adults CN1 protein was almost undetectable in
serum, while in EDTA-plasma significant amounts were
detected. In contrast, CN1 protein was easily detected in
both serum and EDTA plasma from children (Fig. 2).
Although CN1 activity was significantly lower in children
than in adults, similar amounts of CN1 protein were
detected in EDTA plasma.
Since CN1 protein was always detected in plasma but,
with the exception of one individual, not in serum of adults,
our data might suggested that serum CN1 is present in
different conformations. Accordingly, we added DTT to
sera of adults to potentially stabilize CN1 and assessed if
detection of CN1 by ELISA occurred under this condition.
DTT dose-dependently increased OD450 values, suggest-
ing that detection of CN1 in serum by ELISA depends on
the conformation the protein (Fig. 3).
Inasmuch as the amount of CN1 protein in serum was
significantly higher in children compared to adults and
addition of DTT increased the detection of CN1 in ELISA,
we used Westernblot analysis to determine whether
monomeric CN1 was more prevalent in children than
adults. Under non-reducing conditions two immune-reac-
tive bands with apparent molecular weight of approxi-
mately 150 and 65 kDa were observed. The molecular
weight of the latter band is in concordance with that of
monomeric CN1. There was no consistent difference in the
amount of monomeric CN1 in serum of adults and that of
children. In two out of three children, a prominent 61 kDa
band was also detected, which was markedly less abundant
Table 1 CN1 activity in serum and CSF for carnosine and homo-
carnosine as substrate
Material Age
(years)
CN1 activity
with
carnosine as
substrate
[lmol/ml/h]
N CN1 activity with
homocarnosine
as substrate
[lmol/ml/h]
n
Serum 0–1 0.34 ± 0.24 10 \0.05 5
2–3 0.63 ± 0.4 12 \0.05 6
4–10 1.3 ± 0.9 30 0.12 ± 0.06 14
11–20 2.3 ± 1.2 20 0.14 ± 0.09 25
Above 20 3.2 ± 0.9 94 0.12 ± 0.04 16
CSF 0–1 0.07 ± 0.006 5 \0.05 3
2–3 0.17 ± 0.08 10 0.08 ± 0.02 5
4–10 0.27 ± 0.15 14 0.09 ± 0.05 9
11–20 0.35 ± 0.2 10 0.07 ± 0.03 9
Above 20 0.8 ± 0.22 15 0.11 ± 0.09 11
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Fig. 2 CN1 was measured by ELISA in serial dilutions of serum
(open circles) or EDTA plasma (closed circles) obtained from
children (n = 11) and adults (n = 10) as described in materials and
methods. CN1 concentrations were determined in the linear part of
the dilution curve. The results of all individual samples are depicted;
the mean of each group is depicted as a line. Statistical significance
was determined by Student’s t test, a P value\0.05 was considered as
significant
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Fig. 3 Infuence of DTT on the detection of CN1 protein in serum of
adults. Undiluted serum was added in the presence of different
concentration of DTT to the ELISA plates. Thereafter, the ELISA was
performed as described. The result of a representative serum obtained
from an adult is depicted. At least three different sera were tested;
they gave essentially the same results
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in serum of adults (Fig. 4a). Under reducing conditions the
upper band was shifted to approximately 130 kDa while
the 65 kDa band did not change in molecular weight.
Although addition of DTT clearly changed the conforma-
tion of CN1, as revealed by the change in mobility during
electrophoreses, CN1 was not completely reduced by DTT
to the monomeric form. To assess if the 150 kDa band was
a differentially N-glycosylated CN1 isoform, the samples
were treated with PNGase. The 150 kDa band was partially
resistant to PNGase as revealed by the appearance of a 120
and 130 kDa band. The latter was likely due to the pres-
ence of DTT in the denaturation buffer which was required
for PNGase treatment. The 65 kDa band was shifted to
61 kDa after PNGase treatment, suggesting that the 61 kDa
band present in serum of children is most likely a mono-
meric CN1 isoform completely or partially devoid of N-
glycosylation (Fig. 4b).
We next assessed in a different cohort of children if
there was a difference in the amount of CN1 protein in
serum, EDTA plasma and CSF within the same individual.
We also assessed serum CN1 activity with carnosine as
substrate in this cohort. In children below 1 year of age
CN1 activity was not detectable. Consistent with this
finding, CN1 protein was either not detectable by ELISA or
was present in very small amounts when EDTA plasma
was used. In general, the amount of CN1 protein was
higher in EDTA plasma compared to serum. In CSF CN1
protein concentrations were lower than in serum. There
was no clear correlation between CN1 activity and the
amount of CN1, either when measured in EDTA plasma or
when measured in serum (Table 2).
Competition experiment with both substrates in serum
To assess the ability of CN1 to utilize carnosine or
homocarnosine, we measured CN1 activity with different
combinations of carnosine and homocarnosine in serum
samples obtained from healthy adults. The addition of
increasing amounts of homocarnosine reduced CN1 activ-
ity with carnosine significantly in both serum (Fig. 5) and
CSF (data not shown) compared to carnosine as sole sub-
strate. The addition of 80 lmol/l homocarnosine decreased
the carnosinase activity for carnosine from 2.6 ± 0.15 to
1.8 ± 0.1 lmol/ml/h significantly (n = 5; P \ 0.01; Stu-
dent’s t test) and 800 lmol/l homocarnosine decreased the
activity to 0.6 ± 0.09 lmol/ml/h (n = 5; P \ 0.01; Stu-
dent’s t test) In contrast, another dipeptide (Leu-His) which
is not degraded by carnosinase did not show any effect on
CN1 activity (Fig. 5). Inhibition was immediate but
reversible and enzyme activity recovered within 5–10 min.
Hence, our results indicate that CN1 activity toward car-
nosine is inhibited by homocarnosine. Inhibition was
dependent upon the amounts and ratio of both dipeptides in
serum (Table 3). For all samples, carnosine turnover at a
substrate concentration of 160 lM carnosine was between
1.3 and 1.8 lmol/ml/h and addition of homocarnosine
lowered the degradation significantly (P \ 0.01, Student’s
t test). Activity decreased to 0.8–1.2 lmol/ml/h when
homocarnosine concentration was added (320 lM), and to
180
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+ -PNGase
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Fig. 4 Expression of CN1 in serum of adults and children. Albumin
and IgG depleted serum was subjected to SDS–PAGE and West-
ernblotting. a The samples were either treated with DTT (reducing
conditions) or were left untreated. Under reducing conditions two
bands with apparent molecular weight of 130 and 65 kDa respectively
were detected. The latter band is in concordance to the molecular
weight of monomeric CN1. Under non-reducing conditions immuno-
reactive band of approximately 150 and 65 kDa were detected. Note
the presence of an additional 61 kDa band in serum of children. This
was observed in two out of three children, while in adults (n = 3) this
band was either not detected or weakly expressed. b Serum of a child
was either treated with PNGase to remove N-glycosylation, or left
untreated. SDS–PAGE was performed under non-reducing conditions
for the untreated sample. Since DTT was present in denaturation
buffer for PNGase, SDS–PAGE for the treated sample was performed
under reducing conditions. The 150 kDa band was partly resistant to
PNGase as demonstrated by the appearance of a 120 kDa band. The
130 kDa band occurred due to the presence of DTT in the
denaturation buffer. The 65 kDa band was shifted to 61 kDa,
corresponding to the lower band in the untreated serum. The lower
band in the treated sample may represent a completely N-deglyco-
sylated CN1 monomer or degradation product. The result of a
representative blot (n = 3) is depicted in a, b
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0.4–0.8 lmol/ml/h with homocarnosine concentrations of
800 lM. Similar results were obtained for lower carnosine
concentrations (data not shown).
We analyzed homocarnosine and carnosine degradation
and histidine formation in samples with either carnosine as
sole substrate or with both homocarnosine and carnosine
together. When both substrates were available, both were
degraded simultaneously (Fig. 6), but carnosine degrada-
tion and histidine formation were reduced in the presence
of homocarnosine. We tested this effect for carnosine
concentrations of 40, 80, 160, 320 and 960 lM in combi-
nation with homocarnosine concentrations of 160, 80 and
0 lM. Independent of the ratio of carnosine to homocar-
nosine, we observed significantly lower CN1 activities
(P \ 0.01; Student’s t test.) in the presence of homocar-
nosine (data not shown), even when carnosine concentra-
tion was 12-fold higher than homocarnosine concentration.
Activity of recombinant human CN1
To confirm that carnosine and homocarnosine turnover in
serum reflected CN1 activity and that no other serum
component influenced the enzymatic reaction, we repeated
the results with the recombinant human CN1. Without
homocarnosine the apparent Km for the conversion of
carnosine to ß-alanine and L-histidine was 175 lM carno-
sine and Vmax about 440 pmol/min/lg. The addition of
80 lM homocarnosine lowered Vmax to 356 pmol/min/lg
and increased Km to a concentration of 210 lM carnosine.
Enzyme activity in the presence of 160 lM carnosine and
80 lM homocarnosine was 264 pmol/min/lg (±22.4;
n = 5) whilst increasing homocarnosine to 160 lM low-
ered the maximal activity significantly (P \ 0.01; Stu-
dent’s t test) to 122 pmol/min/lg (±16.2; n = 5). An
activity of 40 pmol/min/lg (±5.3; n = 5) was observed
when homocarnosine was present in a concentration of
480 lM. The estimated Ki for homocarnosine was 240 lM
which shows a reduced affinity of CN1 toward carnosine in
the presence of homocarnosine.
Carnosine turnover and homocarnosine concentrations
in vivo
The correlation between carnosine turnover and homocar-
nosine concentrations in serum of control individuals is
depicted in Fig. 7. Higher homocarnosine concentrations
were associated with lower CN1 activity, in line with an
inhibitory effect of homocarnosine on CN1 activity.
Table 2 Serum CN1 activity
and protein concentration in
serum, EDTA plasma and CSF
of children
a Age is provided in years as
otherwise stated in months or
days
b CN1 activity was measured
three times and is expressed in
lmol/ml/h
c CN1 concentrations are
expressed as ng/ml
Agea CN1 activityb CN1 protein CN1 protein CN1 protein
Plasmac Serumc CSFc
6 days 0 Not detectable Not detectable Not detectable
2 months 0 24 Not detectable Not detectable
6 months 0 34 ± 5 Not detectable Not detectable
9 0.3 ± 0.04 15,018 ± 1,852 788 ± 392 262 ± 35
1 0.01 ± 0.001 199 ± 21 Not detectable Not detectable
1.5 0.1 ± 0.02 170 ± 78 39 ± 1 50 ± 14
2 0.1 ± 0.02 107 ± 12 90 ± 20 42 ± 23
4 2.6 ± 0.2 520 ± 277 304 ± 84 37 ± 18
6 1.8 ± 0.2 2,384 ± 821 1,617 ± 721 190 ± 11
9 0.4 ± 0.05 2,216 ± 647 1,704 ± 856 288 ± 7
12 2.2 ± 0.2 1,307 ± 551 450 ± 20 28
13 1.4 ± 0.1 11,650 ± 403 7,980 ± 2,458 181 ± 48
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carnosine and an additional
dipeptide. Carnosine
degradation in serum can be
lowered by the addition of
homocarnosine (striped)
whereas the addition of another
dipeptide Leu–His (gray) has no
effect on carnosine degradation
(n = 5). With increasing
amount of homocarnosine, CN1
activity for carnosine
degradation decreases
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Discussion
In the present study we provide further data on CN1
activity and protein concentrations in serum and cerebro-
spinal fluid (CSF) of children and adults. The main findings
of this study are the following. First, in children CN1
activity in serum is lower than adults but this is not
reflected by differences in CN1 protein concentrations.
Second, CN1 is present in different allosteric conforma-
tions in children and adults. This is suggested by the
observation that CN1 is always detected in sera of children
by ELISA, while 90% of the adults were negative. In
contrast, both children and adults were positive in CN1
ELISA when EDTA-plasma was used. Third, in all sera
homocarnosine dose-dependently inhibited CN1 activity
toward carnosine. The amount of homocarnosine in serum
and CSF correlated inversely with CN1 activity.
Whereas CN1 activity for carnosine as substrate is well
characterized (Teufel et al. 2003), little is known about its
role in homocarnosine metabolism. CN1 is the only known
enzyme with relevant activity toward both dipeptides, but
the biological basis of the divergent concentrations of
carnosine and homocarnosine in blood (low amounts of
both dipeptides) and CNS (low amounts of carnosine but
higher amounts of homocarnosine) has not been well
characterized. Enzyme analyses carried out in the present
study showed that homocarnosine turnover in blood is
much lower than carnosine. CN1 activity in serum and CSF
differ for carnosine and homocarnosine. In all age groups,
CN1 activity for carnosine is four to six times higher in
serum than in CSF, while this effect is not observed for
Table 3 CN1 activity in serum with a substrate combination of carnosine and homocarnosine
Ratio carnosine–homocarnosine Substrate concentration Activity [lmol/ml/h]
Carnosine (lM) Homocarnosine (lM) Control 1 Control 2 Control 3 Control 4 Average
80 – 1.2 ± 0.1 0.9 ± 0.11 1.2 ± 0.1 1.3 ± 0.12 1.2
160 – 1.8 ± 0.12 1.8 ± 0.14 1.5 ± 0.14 1.3 ± 0.4 1.6
480 – 2.6 ± 0.1 2.8 ± 0.12 2.1 ± 0.2 3.1 ± 0.25 2.7
1:2 160 320 0.9 ± 0.01 1.2 ± 0.1 1.1 ± 0.26 0.8 ± 0.1 1.0
1:2 80 160 0.7 ± 0.14 0.7 ± 0.1 1.1 ± 0.2 0.9 ± 0.17 0.9
1:5 160 800 0.7 ± 0.12 0.8 ± 0.21 0.4 ± 0.06 0.6 ± 0.08 0.6
1:5 80 400 0.7 ± 0.14 0.7 ± 0.2 0.6 ± 0.06 0.6 ± 0.1 1.0
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Fig. 6 Carnosine degradation (triangle) and histidine formation
(square) with and without the addition of homocarnosine (open
square). Carnosine degradation is slower in the addition of homo-
carnosine compared to carnosine as the only substrate
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Fig. 7 CN1 activity with carnosine as substrate in serum and
homocarnosine concentration in plasma was measured in healthy
adults. Carnosinase degradation is correlated with homocarnosine
concentration
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homocarnosine as substrate. Although ELISA demon-
strated higher amounts of CN1 protein in serum than in
CSF, this does not sufficiently explain the biochemical
patterns observed in vivo.
Importantly, our study demonstrates that CN1 seems to
be present in a different allosteric conformation in children
as compared to adults. Several arguments are in favor of
this assumption. First, CN1 activity was significantly lower
in children compared to adults, yet CN1 protein was sel-
domly detected in serum of the latter, while in all sera
obtained from children CN1 protein was measured by
ELISA. Because EDTA plasma of adults was always
positive for CN1, we propose that in sera of adults the CN1
protein is either masked or not in the appropriate confor-
mation for detection by ELISA. Second, addition of DTT
to the sera significantly increased the OD450 values, sug-
gesting that conformational changes of CN1 render the sera
to become positive in ELISA.
It might be argued that addition of DTT confers CN1
dimers into monomers, and that the CN1 ELISA is pref-
erentially measuring monomeric CN1. Differences
between children and adults in the serum CN1 ELISA
therefore could be due to differences in mono versus
dimeric CN1. Westernblot analysis, however, demon-
strated that there was no consistent difference in mono-
meric CN1 between sera from children and adults. We did,
however, observe the presence of a monomeric CN1 iso-
form that is devoid of N-glycosylation. This isoform was
abundantly present in two out of three sera from children
but was weakly present or absent in sera from adults. It
should also be emphasized that if the CN1 ELISA is only
recognizing monomeric CN1, a positive ELISA in EDTA
plasma would not be expected.
To our knowledge, this is the first report suggesting that in
vivo CN1 is present in different allosteric conformations.
Although our study does not provide a structural explanation
for the different allosteric conformations, recently a study by
Vistoli et al. (2006) has postulated that citrate ions can alter
the conformation and activity of CN1. Given the fact that in
the active center of CN1 different metal ions may be bound, it
is conceivable that this might result in different allosteric
conformations. Qualitative differences in, or the lack of,
metal ion binding might explain a different CN1 conforma-
tion and low activity in children. The influence of metal ion
binding, e.g. Mn or Cd, on CN1 activity has already been
demonstrated (Lenney et al. 1982).
The results of the present study also indicate that
dipeptide and dipeptidase patterns observed in blood and
CSF are partially explained by a competitive inhibitory
effect of homocarnosine on CN1. In control subjects there
was a negative correlation between carnosine turnover and
homocarnosine concentrations. Competition experiments
in serum and with recombinant human CN1 showed that
the presence of homocarnosine reduced CN1 activity for
carnosine even at low homocarnosine concentrations
whereas CN1 activity was unaffected by the addition of
histidine or Leucine–Histidine (Leu–His) dipeptide. Hence,
the correlation observed in controls was not explained by a
cofactor or confounding variables. Rather, reduced carno-
sine degradation in the presence of homocarnosine is most
likely due to competition of both substrates binding at the
same active site of the CN1 enzyme. Since the turnover of
homocarnosine is lower and carnosine cannot enter the
active site while homocarnosine binds, the degradation of
carnosine is also lowered. Even a 12-fold higher carnosine
concentration compared to homocarnosine did not out-
compete homocarnosine in binding to the enzyme. The
inhibitory effect is reversible since after cleavage or
removal of homocarnosine, carnosine metabolism is com-
parable to those samples in the absence of homocarnosine.
Decreased carnosinase activity was not found for the
dipeptide Leu–His showing that the inhibition is due only
to homocarnosine. Our findings are consistent with those of
Margolis et al. (1979) who demonstrated an inhibitory
effect of homocarnosine on carnosinase.
The physiological role of carnosine is still uncertain.
Carnosine is mainly found in skeletal muscle and the
concentration is closely related to muscle activity. Carno-
sine presumably exerts antioxidative effects and we
recently demonstrated that a leucine repeat polymorphism
in the CN1 protein, affecting CN1 secretion across the cell
membrane, is associated with susceptibility to developing
diabetic nephropathy Janssen et al. (2005). Homocarnosine
is thought to be a precursor for the neurotransmitter
GABA, and this may explain the relatively high concen-
trations of homocarnosine in the brain and consequently
the reduced dipeptidase activity toward carnosine.
In conclusion, homocarnosine appears to be an effective
regulator of CN1 activity, and therefore its concentration
might be an important metabolic parameter affecting the
carnosine pathway. Moreover, a possible therapeutic option
of homocarnosine for patients at risk for diabetic
nephropathy has to be considered with caution. On the one
hand, we would expect that homocarnosine treatment could
reduce the serum degradation of carnosine. On the other
hand, high concentrations of homocarnosine might lead to
high concentrations of its degradation products c-amino-
butyric acid (GABA) and histidine. Histidine can be easily
converted into histamine and the impact on autonomic
nerve activity would be unpredictable and could result in
further progression of renal insufficiency, since progressive
renal disease has been shown to be associated with
increased nerve activity.
However, the regulatory mechanisms of carnosine syn-
thesis and degradation, its physiological role and a possible
relevance of reduced activity require further investigation.
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